Claritin Patent Case May Define Value Of Metabolite Patents
Executive Summary
Innovators will still have a viable method for protecting metabolites if the Claritin patent ruling is upheld, a federal appellate court judge said April 8
You may also be interested in...
Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims
Metabolites of known drugs may not receive patent protection through broad compound claims, a D.C. federal appeals court ruled Aug. 1 in the Claritin patent infringement case
Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims
Metabolites of known drugs may not receive patent protection through broad compound claims, a D.C. federal appeals court ruled Aug. 1 in the Claritin patent infringement case
Schering Claritin Patent Ruling Unlikely To Affect Clarinex Exclusivity
The outcome of Schering-Plough's Claritin patent litigation is unlikely to have a significant effect on the exclusivity for the successor drug Clarinex